Abbott, J&J: tops in sales force quality

Share this article:
Abbott Laboratories, followed by Johnson & Johnson and Eli Lilly, were ranked the top pharma companies in overall sales force quality by primary care physicians, according to TargetRx's “Sales Force Analysis” report. Genentech, followed by Novartis and TAP Pharmaceutical Products, were the top-ranked companies in overall sales force quality by specialty physicians, the report found.

The TargetRx analysis benchmarked 11 pharmaceutical sales forces that call on primary care physicians and 15 pharmaceutical sales forces that call on physician specialists against each other. 
Drawing conclusions based on 2005 performance and sales force effectiveness to physician prescribing, the analysis aims to provide pharma companies with opportunities to improve their market position, according to Mike Luby, TargetRx's CEO.

“We are not just polling physicians and telling pharmaceutical companies what physicians are saying about them,” Luby told MM&M. “With our patented approach, we are able to determine how things you are doing in the marketplace drive market share.” 

Key drivers of the TargetRx data included detail piece effectiveness, which measures how well the detail piece increases prescribing. 

“Schering-Plough really distinguishes itself in this area and is the top company on detail piece effectiveness,” Luby said. 

Another driver of data is identifying the appropriate patient for therapy. “Among primary care specialists, Lilly ranks No. 1 and Abbott ranks No. 2 in this category. Among specialty physicians, Abbott ranks No. 1 and Lilly ranks No. 2,” he explained.

Companies included in the benchmarking were Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Genentech, GlaxoSmithKline, Hoffman-La Roche, Johnson & Johnson, Merck, Novartis, Pfizer, Sanofi-Aventis, Schering-Plough, TAP and Wyeth. 
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?